To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:7 Issue:8 Number:17 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
RCT
ACE Report #10576
Ace Report Cover Cannabis

Dronabinol effective in reducing neuropathic pain in multiple sclerosis after 48-week treatment


How to Cite

OrthoEvidence. Dronabinol effective in reducing neuropathic pain in multiple sclerosis after 48-week treatment. ACE Report. 2018;7(8):17. Available from: https://myorthoevidence.com/AceReport/Report/10576

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Dronabinol is a safe long-term treatment option for neuropathic pain patients

Eur Neurol. 2017;78(5-6):320-329.

Contributing Authors: S Schimrigk M Marziniak C Neubauer EM Kugler G Werner D Abramov-Sommariva

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

240 patients who had neuropathic pain that was associated with multiple sclerosis (MS) were randomly assigned to receive either dronabinol 7.5-15.0 mg daily for 16 weeks, or its respective placebo with the identical schedule. No significant differences in pain reduction and quality of life improvement were found in patients that received dronabinol compared to those that received placebo. In a fol...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.